ARS Pharmaceuticals IncSPRY
Price$4.31

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value not published yet, our data-reliability standards weren't met; method estimates belowbased on filings through 30 Jun 2026
Market Price $4.31Price as of 30 Sep 2026

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 5.0% (near-term consensus, capped) · years 2–5: 77.8%/yr (balance of the path).60.0% per year
Years 6–10: glide to demonstrated growth
Per-year rates
Yr 666.2%Yr 754.7%Yr 843.1%Yr 931.6%Yr 1020.0%
77.8% → 20.0%
Years 11–20: glide to long-run rate
Per-year rates
Yr 1118.3%Yr 1216.6%Yr 1314.9%Yr 1413.2%Yr 1511.5%Yr 169.8%Yr 178.1%Yr 186.4%Yr 194.7%Yr 203.0%
20.0% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Discount rate (cost of equity) 9.5%
Volatility vs market (adjusted beta)1.02

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions Sandbox Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetARS Pharmaceuticals IncSPRYHealth Care
Valuation
P/E—
P/S3.5×
P/B32.7×
EV / Revenue4.3×
EV / EBITDA-4.6×
Profitability
Gross margin72.2%
Operating margin-264.8%
Net margin-184.2%
FCF margin-168.1%
Returns
ROE-1,721.8%
ROA-86.3%
ROIC—
Growth
Revenue growth (YoY)31.2%
5-yr fwd EPS growth81.9%
Financial strength
Debt / Equity7.73×
Current ratio3.48×
Altman Z-Score-2.9
Interest coverage—
Dividend yield—

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.